Astellas' Pompe disease gene therapy placed on hold by FDA - Fierce Biotech

The FDA has slammed the breaks on a phase 1/2 study of the Japanese pharma's Pompe disease gene therapy to investigate a report of nerve damage.
https://www.google.com/url?rct=j&sa=t&url=https://www.fiercebiotech.com/biotech/astellas-gene-therapy-strategy-faces-fresh-setback-fda-puts-pompe-disease-drug-hold&ct=ga&cd=CAIyGmEyNDJjNTAxZWU3OTQyNzI6Y29tOmVuOlVT&usg=AOvVaw0Us2pb5P_bla2kWWvldku3